Corient Private Wealth LLC Reduces Position in Becton, Dickinson and Company (NYSE:BDX)

Corient Private Wealth LLC lowered its holdings in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 15.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 244,579 shares of the medical instruments supplier's stock after selling 44,773 shares during the quarter. Corient Private Wealth LLC owned 0.08% of Becton, Dickinson and Company worth $55,488,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also bought and sold shares of BDX. Bank of Jackson Hole Trust bought a new stake in shares of Becton, Dickinson and Company in the 4th quarter worth about $25,000. Sierra Ocean LLC purchased a new position in Becton, Dickinson and Company in the 4th quarter worth about $29,000. Picton Mahoney Asset Management increased its stake in Becton, Dickinson and Company by 61.4% in the 4th quarter. Picton Mahoney Asset Management now owns 142 shares of the medical instruments supplier's stock worth $32,000 after buying an additional 54 shares during the period. Hopwood Financial Services Inc. purchased a new position in Becton, Dickinson and Company in the 4th quarter worth about $39,000. Finally, Versant Capital Management Inc increased its stake in Becton, Dickinson and Company by 54.1% in the 4th quarter. Versant Capital Management Inc now owns 208 shares of the medical instruments supplier's stock worth $47,000 after buying an additional 73 shares during the period. Institutional investors own 86.97% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts recently commented on BDX shares. Barclays raised their price target on shares of Becton, Dickinson and Company from $278.00 to $279.00 and gave the stock an "overweight" rating in a research note on Friday, February 14th. Piper Sandler raised their price target on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an "overweight" rating in a research note on Tuesday, January 28th. Finally, StockNews.com raised shares of Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research report on Wednesday, March 5th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $278.29.

Remove Ads

Becton, Dickinson and Company Stock Up 0.1 %

NYSE BDX traded up $0.15 during trading on Thursday, reaching $231.94. 1,636,172 shares of the company's stock traded hands, compared to its average volume of 1,525,683. Becton, Dickinson and Company has a 12-month low of $218.75 and a 12-month high of $251.99. The firm has a market cap of $66.60 billion, a price-to-earnings ratio of 38.53, a price-to-earnings-growth ratio of 1.63 and a beta of 0.35. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.13 and a quick ratio of 0.63. The company's 50 day simple moving average is $232.68 and its two-hundred day simple moving average is $232.12.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its quarterly earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share for the quarter, beating analysts' consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. As a group, sell-side analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 31st. Stockholders of record on Monday, March 10th will be issued a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a dividend yield of 1.79%. The ex-dividend date of this dividend is Monday, March 10th. Becton, Dickinson and Company's dividend payout ratio (DPR) is 69.10%.

Becton, Dickinson and Company announced that its Board of Directors has approved a stock repurchase program on Tuesday, January 28th that authorizes the company to repurchase 10,000,000 shares. This repurchase authorization authorizes the medical instruments supplier to buy shares of its stock through open market purchases. Shares repurchase programs are often an indication that the company's board believes its shares are undervalued.

Insider Activity

In related news, EVP Richard Byrd sold 459 shares of the business's stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $230.00, for a total value of $105,570.00. Following the completion of the sale, the executive vice president now owns 6,952 shares of the company's stock, valued at approximately $1,598,960. The trade was a 6.19 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP David Shan sold 500 shares of the business's stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $240.00, for a total transaction of $120,000.00. Following the completion of the sale, the executive vice president now directly owns 5,741 shares of the company's stock, valued at approximately $1,377,840. The trade was a 8.01 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 4,984 shares of company stock valued at $1,147,865 in the last three months. 0.36% of the stock is currently owned by corporate insiders.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.